Alfred Sandrock - Articles and news items

Biogen Idec logo

Richard A. Rudick joins Biogen Idec as Vice President, Development Sciences, Value-Based Medicine

Industry news / 12 May 2014 / Biogen Idec

Biogen Idec announced that Richard (Rick) A. Rudick, M.D., has joined the company as vice president, Development Sciences, Value-Based Medicine…

Biogen Idec logo

New TYSABRI® analysis at AAN Annual Meeting shows improved walking speed in significant number of MS patients

Industry news / 1 May 2014 / Biogen Idec

Biogen Idec announced that a post hoc analysis of data from the AFFIRM study shows TYSABRI® (natalizumab) significantly increased the proportion of relapsing-remitting multiple sclerosis patients with confirmed improvement in walking speed…

Biogen Idec logo

New data reinforce efficacy of TECFIDERA® (Dimethyl Fumarate) in MS patients with high disease activity

Industry news / 30 April 2014 / Biogen Idec

Additional real-world data show tolerability profile consistent with pivotal studies…

Biogen Idec logo

Quintiles and Biogen Idec announce comprehensive 
clinical development partnership

Industry news / 24 April 2014 / Biogen Idec

Quintiles and Biogen Idec have entered into a five-year strategic clinical development agreement…

Biogen Idec logo

Biogen Idec to present new clinical data from its robust neurology portfolio at AAN Annual Meeting

Industry news / 14 April 2014 / Biogen Idec

Biogen Idec will present more than 60 company-sponsored platform and poster presentations on data supporting its marketed and investigational therapies for neurological diseases at the 66th American Academy of Neurology Annual Meeting…

Biogen Idec logo

New Tysabri® data show earlier treatment and longer-term use result in significant reductions in MS disease activity

Industry news / 3 October 2013 / Biogen Idec

“These analyses build upon a growing body of evidence that demonstrates greater clinical benefits for people with MS when TYSABRI is initiated earlier in the course of the disease…”

Biogen Idec logo

Biogen Idec and Elan submit applications for first-line use of TYSABRI in anti-JCV antibody negative patients with MS

Industry news, News / 16 January 2013 / Biogen Idec

Biogen Idec and Elan have submitted applications to the U.S. FDA…

Biogen Idec logo
Biogen Idec logo

TYSABRI® (natalizumab) Data at ECTRIMS Reaffirm Positive Effects of Treatment for People with Relapsing Forms of MS

Industry news, News / 11 October 2012 / Biogen Idec

Results from 11 company-sponsored TYSABRI presentations…

Biogen Idec logo
Biogen Idec logo

Biogen Idec and Abbott present positive data for Daclizumab HYP from Select Phase 2b trial at ECTRIMS/ACTRIMS

Industry news, News / 22 October 2011 / Biogen Idec

Biogen Idec and Abbott announced additional results from the SELECT Phase 2b trial…


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...